What compounds target PRKCQ?

BiohacksAI has identified 31 compounds that interact with PRKCQ (protein kinase C, theta). Top compounds include: alvocidib, tozasertib, bosutinib, midostaurin, nintedanib. Each compound is ranked by evidence score derived from PubMed bioassay confidence and assay count.

What is PRKCQ (protein kinase C,)?

PRKCQ is protein kinase C, theta. It is a molecular target for 31 compounds documented in PubMed bioassay data. UniProt ID: Q9WTQ0. NCBI Gene ID: 85420.

PRKCQ

MOLECULAR TARGET

protein kinase C, theta

UniProt: Q9WTQ0 NCBI Gene: 8542031 compounds

PRKCQ (protein kinase C, theta) is targeted by 31 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting PRKCQ

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#	Compound	Confidence	Active Assays
1	alvocidib	4.52	91
2	tozasertib	4.33	75
3	bosutinib	4.08	58
4	midostaurin	3.85	46
5	nintedanib	3.61	36
6	tae 684	3.43	30
7	pexidartinib	3.43	30
8	gf 109203	3.40	29
9	dovitinib	3.09	21
10	jnj 7706621	3.09	21
11	upadacitinib	3.09	21
12	lestaurtinib	3.04	20
13	pf 03758309	3.00	19
14	ruboxistaurin	2.94	18
15	k 252a	2.83	16
16	pf 00562271	2.77	15
17	sotrastaurin	2.77	15
18	capivasertib	2.77	15
19	curcumin pyrazole	2.77	15
20	crenolanib	2.71	14
21	gsk 690693	2.64	13
22	ast 487	2.56	12
23	isoxanthohumol	2.30	9
24	su 014813	2.20	8
25	y 39983	2.20	8
26	enzastaurin	2.08	7
27	lgh 447	1.95	6
28	ucn 01	1.79	5
29	hydroxyfasudil [Supplementary Concept]	1.10	2
30	myricetin-3-O-galactopyranoside [Supplementary Concept]	0.69	1
31	Sphingosine	0.69	1

About PRKCQ as a Drug Target

PRKCQ (protein kinase C, theta) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 31 compounds with documented PRKCQ interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

PRKCQ inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.